

(a)Pfizer



(b)GlaxoSmithKline

	Mental Disorders
	Wounds and Injuries
	Chemically-Induced Disorders
	Occupational Diseases
	Pathological Conditions, Signs and Symptoms
	Animal Diseases
	Disorders of Environmental Origin
	Immune System Diseases
	Endocrine System Diseases
	Nutritional and Metabolic Diseases
	Skin and Connective Tissue Diseases
	Congenital, Hereditary, and Neonatal Diseases and Abn
	Hemic and Lymphatic Diseases
	Cardiovascular Diseases
	Female Urogenital Diseases and Pregnancy Complicatic
	Male Urogenital Diseases
	Eye Diseases
	Nervous System Diseases
	Otorhinolaryngologic Diseases
	Respiratory Tract Diseases
	Stomatognathic Diseases
	Digestive System Diseases
	Musculoskeletal Diseases
	Neoplasms
	Parasitic Diseases
	Virus Diseases
	Bacterial Infections and Mycoses



(c)Merck Sharp & Dohme Corp.




(d)AstraZeneca



(e)Novartis Pharmaceuticals



(f)Eli Lilly and Company



0 10 20 30 40 50 60 70 80 90 100

(g)Boehringer Ingelheim



(h) Hoffmann-La Roche



(i) Sanofi



(j)Bristol-Myers Squibb



(k)Novartis



(I)Bayer




(m)Genentech, Inc.



(n)Amgen



(o)Novo Nordisk A/S



(p)Gilead Sciences



(q)Takeda



(r)Astellas Pharma Inc



(s)Celgene Corporation



(t)Johnson & Johnson Pharmaceutical Research & Development, L.L.C.



Figure S2. Therapeutic area maps for the top 20 pharmaceutical firms. The horizontal and vertical axes indicate year and 27 therapeutic areas, respectively. A filled cell indicates at least one clinical trial in the therapeutic area in the vertical axis started in the year in the horizontal axis.